The Effect of Sugammadex on the Outcome After Colorectal Cancer Surgery

Ajou University School of Medicine

Status: Completed

Conditions: Outcome, Fatal

Treatments: Drug: Sugammadex

Study type: Observational

Funder types: Other

Identifiers

NCT03619759

AJIRB-MED-MDB-18-36

Details and patient eligibility

About

This study is retrospective study. The purpose of this study is checking the effect of sugammadex on the outcome after colorectal surgery. The outcome is compared among the 2 groups, sugammadex group and non-sugammadex group. The primary parameters of outcome are length of stay, readmission rate, postoperative complications, time interval for first successful oral intake.

Full description

Abdominal surgery, like colorectal surgery, needs more than moderate neuromuscular block during surgery. After the surgery, reversal agent of neuromuscular blocking agent is given almost every pateints who underwent general anesthesia.

Classic reversal agent is cholinesterase inhibitor, like pyridostigmine and neostigmine. Its action mechanism is competetive antagonist of rocuronium. But cholinesterase inhibitor cannot make complete reversal in moderate or deep neuromuscular block. Its incomplete reversal which is called residual block cause respiratory complications and prolongation hospital stay.

Sugammadex has different mechanism compared to cholinesterase inhibitor. It captures neuromuscular agent, especially rocuronium, and prevent rocuronium's action. Even in deep neuromuscular block, sugammadex can reverse the action of rocuronium, and its reversal effect is fater and more reliable compared to cholinesterase inhibitor.

Previous studies focused on only short term outcome of sugammadex, like postanesthetic care unit (PACU) discharge time, respiratory complications in PACU.

But in this study, longer term outcome will be comapred between sugammadex group and cholinesterase inhibitor group (pyridostigmine).

Enrollment: 585 patients

Sex: All

Ages: 21 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Subjects aged 21~80
• Subjects who took colorectal surgery due to colon or rectal cancer from Jan, 2012 to Dec, 2017

Exclusion criteria

• Emergency surgery
• Paraplegia or quadriplegia
• Bedridden state d/t various reason
• Neuromuscular disease
• Combined operation wth other surgery

Trial design

585 participants in 2 patient groups

Sugammadex

Description:

Patients who used sugammadex Sugammadex 1 vial (200mg) intravenous, at the end surgery, before extubation

Treatment:

Drug: Sugammadex

Non-sugammadex

Description:

Patients who didn't use sugammadex Pyridostigmine 15\~20mg intravenous, at the end of surgery, before extubation